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PPeripheral Vascular Disease
Efficacy of Cilostazol After
Endovascular Therapy for Femoropopliteal Artery
Disease in Patients With Intermittent Claudication
Yoshimitsu Soga, MD,* Hiroyoshi Yokoi, MD,* Tomohiro Kawasaki, MD,† Hitoshi Nakashima, MD,‡
Masanori Tsurugida, MD,§ Yutaka Hikichi, MD, Masakiyo Nobuyoshi, MD, FACC, FAHA*
Kitakyusyu, Kurume, Kagoshima, Miyakonojyo, and Saga, Japan
Objectives The purpose of this study was to investigate whether cilostazol reduces restenosis and revascularization after
endovascular therapy (EVT) for femoropopliteal lesions.
Background Cilostazol improves walking distance in patients with intermittent claudication and reduces restenosis after coro-
nary intervention, but its efficacy remains unclear after EVT for femoropopliteal disease.
Methods This study was performed as a multicenter, randomized, open-label clinical trial. Eighty patients (mean age 70.7 
6.2 years, 84% men) with intermittent claudication due to a femoropopliteal lesion were randomly assigned to
receive or not receive cilostazol in addition to aspirin. The primary end point was freedom from target vessel re-
vascularization, and the secondary end points were the rate of restenosis and freedom from target lesion revas-
cularization and major adverse cardiovascular events, defined as all-cause death, myocardial infarction, stroke,
repeat revascularization, and leg amputation.
Results Clinical follow-up information was obtained in all patients. Patient, lesion, and procedural characteristics did not
differ significantly between the 2 groups. Stenting was performed in 36 patients (cilostazol, 16; control, 20; p 
0.36). Freedom from target vessel revascularization at 2 years after EVT was significantly higher compared with
the control group (84.6% vs. 62.2%, p  0.04). The rate of restenosis was lower in the cilostazol group (43.6%
vs. 70.3%, p  0.02), and freedom from target lesion revascularization and major adverse cardiovascular events
was higher in the cilostazol group (87.2% vs. 67.6%, p  0.046, 76.8% vs. 45.6%, p  0.006, respectively).
There was no major bleeding in either group during follow-up period.
Conclusions Cilostazol reduced restenosis and repeat revascularization after EVT in patients with intermittent claudication
due to femoropopliteal disease. (J Am Coll Cardiol 2009;53:48–53) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.020t
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deripheral arterial disease (PAD) has a high prevalence
orldwide. Furthermore, PAD damages the lower extrem-
ties and is complicated by ischemic disease in important
rgans, leading to a 5- or 6-fold increase in mortality due to
oronary artery diseases and stroke in PAD patients (1).
Many PAD patients cannot undergo surgical revascular-
zation and are often treated with endovascular therapy
EVT). The recently introduced nitinol stent has improved
he patency rate for stenting of the femoropopliteal artery
ompared with conventional stents (2). However, the long-
rom the *Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu, Japan;
Department of Cardiology, Shin-Koga Hospital, Kurume, Japan; ‡National Hos-
ital Organization Kagoshima Medical Center, Kagoshima, Japan; §Department of
ardiology, Fujimoto Hayasuzu Hospital, Miyakonojyo, Japan; and the Division of
ardiology, Saga University, Saga, Japan.E
Manuscript received June 25, 2008; revised manuscript received September 8, 2008,
ccepted September 22, 2008.erm patency rate of the nitinol stent is insufficient com-
ared with bypass surgery, and many patients are still at
igh risk for restenosis and require adjuvant systemic
herapy. The 2007 Trans-Atlantic Inter-Society Consensus
I (TASC II) (3) recommended antiplatelet therapy as
harmacotherapy after percutaneous transluminal angio-
lasty and stent implantation. However, most evidence
upporting perioperative antiplatelet therapy has emerged
rom studies on coronary artery disease, and little from EVT
n PAD patients.
Cilostazol is an oral antiplatelet agent that is indicated for
reatment of intermittent claudication (IC) (4), and in
atients with coronary artery disease, cilostazol may lower
estenosis and repeat revascularization after coronary inter-
ention (5). Therefore, we conducted a multicenter trial to
etermine the efficacy of cilostazol in patients treated with
VT for femoropopliteal disease.
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tudy design. The study was performed as a multicenter,
andomized, open-label clinical trial. The effect of cilostazol
n preventing restenosis and repeat revascularization after
reatment of the femoropopliteal disease was evaluated for
4 months by comparison of cilostazol-treated patients and
ntreated patients. Patients with IC who had a de novo
emoropopliteal disease without an inflow lesion, with an
utflow artery, and with symptoms that were not improved
y pharmacotherapy or exercise therapy were enrolled in the
tudy before EVT. Other inclusion criteria were age 18
ears and 80 years old, an ankle-brachial index of 0.9,
nd a percent diameter stenosis (%DS) of 50% by visual
stimate on angiography. Patients with previous lower
xtremity bypass surgery, previous EVT in the femoropop-
iteal artery, acute onset limb ischemia, or severe lower
xtremity ischemic symptoms classified into Rutherford
ategory 4, 5, or 6 were excluded.
Patient randomization and allocation to groups was
erformed using the envelope method by a researcher
ho was not involved in any other aspect of the study and
ho was blinded to the study procedure. The study was
pproved by the Institutional Review Board of each
nstitution, and written informed consent was obtained
rom each subject. This study is registered with the
niversity Hospital Medical Information Network–
linical Trials Registry (UMIN-CTR), as accepted by
he International Committee of Medical Journal Editors
no. UMIN000001434).
tudy procedures. All patients were taking aspirin (81 to
00 mg/day) and ticlopidine (200 mg/day) and had been
ssigned to the cilostazol or noncilostazol (control) group by
he day before EVT or earlier. Patients assigned to the
ilostazol group received cilostazol (200 mg/day) for 2
onsecutive years, with the initial administration of cilosta-
ol on the morning of the day EVT was performed.
emodialysis patients in the cilostazol group received the
rug at a dose of 100 mg. For patients who were already
aking cilostazol before EVT, oral treatment was suspended
hen informed consent was obtained, and they were as-
igned to a group. At the discretion of the surgeon, patients
ere treated with a commercially available balloon or a
utting balloon for stent implantation, and ticlopidine was
topped in these patients on or after the day of the
rocedure. Other patients who underwent stent implanta-
ion received oral ticlopidine for 4 weeks after the
rocedure.
nterventions. All procedures were performed using a 6-
r 7-F sheath. Unfractionated heparin was injected intra-
rterially before the intervention at a dose of 3,000 to 5,000
U and added as required to maintain the active clotting
ime at 200 s. The target lesion was passed with a 0.018-
r 0.014-inch guidewire, the diameter and length of the
alloon or cutting balloon were determined by the surgeon
n the basis of angiography, and the vessel was expanded. tfter balloon angioplasty for at
east 60 s, angiography was con-
ucted and stent implantation
as then performed in patients
ho had a residual stenosis of
30% or a flow-limiting dissec-
ion. A commercially available
elf-expandable stent was used.
he stent type was determined
y the operators, and the stent
ize was chosen to be 1 to 2 mm
arger than the vessel diameter
etermined.
ollow-up. Patients were con-
acted 1 month after the proce-
ure and asked to return for a
linic visit at 6, 12, and 24
onths. At these times, evalua-
ion of restenosis was performed
sing Duplex ultrasonography. Occurrences of bleeding,
yocardial infarction (MI), stroke, repeat revascularization,
nd leg amputation were recorded.
tudy end points. The primary end point was defined as
he freedom from target vessel revascularization (TVR) at 2
ears after treatment, and the secondary end points were
inary restenosis rate and freedom from target lesion revas-
ularization (TLR) and major adverse cardiovascular events
MACE) after 2 years. MACE included death, nonfatal
I, stroke, percutaneous or surgical repeat revasculariza-
ion, and leg amputation. Independent observers blinded to
he medication evaluated the clinical follow-up data. Binary
estenosis was defined as a peak systolic velocity ratio of
2.4 (6). No detectable signal was graded as complete
cclusion.
Procedural success was defined as a residual stenosis of
30% and the absence of a flow-limiting dissection in
ngiography. Myocardial infarction was defined by a signif-
cant elevation of serum biomarkers (troponin above the MI
evel or creatinine kinase levels twice normal) or new
waves on the electrocardiogram. Stroke was defined as
erebral stroke that persisted for at least 24 h and indicated
he occurrence of a neurological deficit. Major bleeding was
efined as a need for transfusion, surgical intervention, or
ypotension requiring inotropic support. The target lesion
as defined as the treated segment from 10 mm proximal to
0 mm distal. The target vessel was defined as the entire
essel of the treated limb. TLR was defined as any repeat
VT for restenosis or other complication of the target
esion with a %DS of50% in angiography (core laboratory
ssessment). TVR was defined as any repeat revasculariza-
ion by EVT or bypass surgery of any segment of the target
essel with a %DS of 50% in angiography.
tatistical analysis. Values are reported as mean SD. All
nalyses were based on an intention-to-treat principle.
ontinuous variables were examined by use of the unpaired
Abbreviations
and Acronyms
EVT  endovascular
therapy
IC  intermittent
claudication
MACE  major adverse
cardiovascular events
MI  myocardial infarction
PAD  peripheral arterial
disease
%DS  percent diameter
stenosis
TLR  target lesion
revascularization
TVR  target vessel
revascularizationtest or nonparametric analysis by the Mann-Whitney U
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Efficacy of Cilostazol in Femoropopliteal Disease December 30, 2008/January 6, 2009:48–53est. Categorical variables were compared by the chi-square
est. Time-dependent outcomes were analyzed by the
aplan-Meier method and compared by log-rank test. A
robability value of 0.05 was considered statistically
ignificant.
esults
aseline characteristics. Eighty patients were enrolled in
he study between October 2004 and October 2005. Two
atients met the exclusion criteria, and therefore 78 patients
ere assigned to the cilostazol (n  39) and control (n 
9) groups (Fig. 1). Procedural success was obtained in 76
97.4%) patients. Two unsuccessful patients in the control
roup required further medical therapy, and 1 showed
orsening of symptoms and received cilostazol after post-
perative day 43. The backgrounds of the patients (Table 1)
nd lesions (Table 2) did not differ significantly between the
groups. Stenting was performed in 36 patients (cilostazol
roup, 16; control group, 20; p  0.36), and the use of
arious commercially available stents was similar between
he 2 groups.
ompliance. Of 39 patients in the cilostazol group, 35
89.7%) were taking cilostazol as directed. Two (5.1%)
atients complained of palpitations, and oral administration
as stopped on post-operative days 24 and 66, respectively.
he other 2 patients had stopped or reduced the dose at
Figure 1 Participant Flow Through the Trialaheir own discretion, and subsequently resumed taking the
orrect dose. Thirteen patients (cilostazol, 7; control, 6)
nderwent implantation of a drug-eluting stent for coronary
rtery disease and received ticlopidine continuously during
he follow-up period. These patients who received triple
ntiplatelet therapy had no major bleeding complications
ver the observation period.
linical end points. Complete follow-up clinical data were
btained from all 78 patients. During the observation
eriod, binary restenosis was found in 43 (55.1%) patients
cilostazol, 43.6% [17 of 39]; control, 70.3% [26 of 37]; p
ackground of Patients Whoid and Di Not Receive Cil stazol
Table 1 Background of Patients WhoDid and Did Not Receive Cilostazol
Variables
Cilostazol ()
(n  39)
Cilostazol ()
(n  39) p Value
Age, yrs 69.8  7.0 71.6  8.1 0.30
Male (%) 31 (79) 34 (87) 0.36
Diabetes mellitus (%) 12 (31) 16 (41) 0.34
Hypertension (%) 19 (49) 19 (49) 0.99
Hypercholesterolemia (%) 15 (38) 11 (28) 0.34
Current smoker (%) 13 (33) 17 (44) 0.35
Renal failure (%)* 8 (21) 7 (18) 0.77
Coronary artery disease (%) 21 (54) 21 (54) 0.99
Previous MI (%) 5 (13) 10 (26) 0.15
Previous CABG (%) 3 (8) 5 (13) 0.46
Previous PCI (%) 16 (41) 17 (44) 0.82
Previous stroke (%) 9 (23) 8 (21) 0.78
Stent/CBA/BA 16/15/8 20/12/5 0.32
Use of stent (%) 16 (41) 20 (51) 0.36
Luminexx/SMART/Wall 5/8/3 6/13/1 0.39
Use of statin (%) 10 (26) 9 (23) 0.79
Use of beta-blocker (%) 7 (18) 4 (10) 0.33
Use of ACEI/ARB (%) 14 (36) 12 (31) 0.63
Pre-procedure ABI 0.59  0.12 0.64  0.15 0.13
Post-procedure ABI 0.81  0.18 0.84  0.16 0.49
Renal failure defined as serum creatinine 1.5 mg/dl.
ABI ankle-brachial index; ACEI angiotensin-converting enzyme inhibitor; ARB angiotensin-
eceptor blocker; BA  balloon angioplasty; CABG  coronary artery bypass graft surgery; CBA 
utting balloon angioplasty; MImyocardial infarction; PCI percutaneous coronary intervention.
etails of Lesions in Patientsho Did and Did Not Receive Cilostazol
Table 2 Details of Lesions in PatientsWho Did and Did Not Receive Cilostazol
Variables
Cilostazol ()
(n  39)
Cilostazol ()
(n  39) p Value
Lesion length, mm 121.1 67.3 131.5 84.0 0.56
Pre-minimum lumen diameter, mm 0.92 0.74 0.94 0.81 0.31
Pre-diameter stenosis, % 78.7 18.1 78.8 18.2 0.99
Pre-reference diameter, mm 4.77 0.72 4.85 0.81 0.65
Post-minimum lumen diameter, mm 3.20 0.98 3.27 0.86 0.77
Post-diameter stenosis, % 28.0 12.5 25.8 12.1 0.46
Post-reference diameter, mm 4.78 0.74 4.74 0.91 0.85
TASC II, A/B/C/D 4/5/10/20 5/3/14/17 0.68
Chronic total occlusion (%) 10 (26) 14 (36) 0.33
Calcified lesion (%)* 8 (21) 6 (15) 0.56
Stent fracture at follow-up (%) 1 of 16 (6) 2 of 20 (10) 0.69
Calcified lesion defined as obvious densities noted within the apparent vascular wall in the
EVT  endovascular therapy; MACE  major adverse cardiovascular events. ngiogram.
TASC II  Trans-Atlantic Inter-Society Consensus II.
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December 30, 2008/January 6, 2009:48–53 Efficacy of Cilostazol in Femoropopliteal Disease.02), and 8 had complete occlusion (cilostazol, 5.1% [2 of
9]; control, 16.2% [6 of 37]; p  0.12). After 24 months,
he freedom from TLR and TVR was significantly higher in
he cilostazol group than in the control group (87.2% vs.
7.6%, p  0.05; 84.6% vs. 62.2%, p  0.04, respectively)
Fig. 2). The freedom from MACE was also significantly
igher in the cilostazol group compared with the control
roup (79.5% vs. 48.7%, p 0.006) (Fig. 3). There were no
ignificant differences in death, MI, stroke, and leg ampu-
ation between the 2 groups; however, repeat revasculariza-
ion was significantly lower in the cilostazol group than in
he control group (18.0% [7 of 39] vs. 43.6% [17 of 39], p
.014) (Table 3). There were 3 deaths during the study: 1 in
he cilostazol group (cardiac death) and 2 in the control
roup (1 cardiac and 1 noncardiac death). In 1 (2.6%)
Figure 2 Freedom From TVR
Freedom from target vessel revascularization (TVR) after 24 months was signifi-
cantly higher in the cilostazol () group (green line) compared with the cilosta-
zol () control group (red line) (84.6% vs. 62.2%, p  0.038).
Figure 3 Freedom From MACE
Freedom from major adverse cardiovascular events (MACE) after 24 months
was significantly higher in the cilostazol () group (green line) compared with
the cilostazol () control group (red line) (79.5% vs. 48.7%, p  0.006).atient in the control group, critical limb ischemia devel-
ped 16 months after the procedure. The resting ankle-
rachial pressure index was significantly better at 24 months
n the cilostazol group compared with the control group
0.81 vs. 0.72, p  0.05) (Fig. 4).
iscussion
he effect of cilostazol after EVT for femoropopliteal
isease was investigated in a multicenter randomized trial.
inary restenosis, TLR, and TVR after 2 years were
ignificantly lower among patients treated with cilostazol
ompared with controls. We used provisional stenting to
etermine appropriate stent implantation on the basis of the
esults of balloon angioplasty. The rate of restenosis in the
ontrol group at 2 years after EVT was 70.3%. Schillinger
t al. (7) reported a restenosis rate of 69.2% at 2 years after
alloon angioplasty with optional secondary stenting (mean
ajor Adverse Cardiovascular Events inatients Who Did and Did Not Receive Cilostazol
Table 3 Major Adverse Cardiovascular Events inPatients Who Did and Did Not Receive Cilostazol
Total
Cilostazol ()
(n  39)
Cilostazol ()
(n  39) p Value
Death (cardiac death) 3 (1) 1 (0) 2 (1) 0.60
Nonfatal MI 0 0 0 0.99
Stroke 1 0 1 0.31
Repeat revascularization 24 7 17 0.014
TLR 17 5 12
TVR 20 6 14
Non-TVR 5 2 3
Surgical
revascularization
1 1 0
Leg amputation 0 0 0 0.99
Major bleeding 0 0 0 0.99
I  myocardial infarction; TLR  target lesion revascularization; TVR  target vessel
evascularization.
Figure 4 Resting Ankle-Brachial Pressure Index
The resting ankle-brachial pressure index was significantly better at 24 months
in the cilostazol () group (green bars) compared with the cilostazol () con-
trol group (red bars) (0.81 vs. 0.72, p  0.046).
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Efficacy of Cilostazol in Femoropopliteal Disease December 30, 2008/January 6, 2009:48–53esion length, 93 mm), similar to the rate in this study. Iida
t al. (8) reported that cilostazol administration after EVT
o patients with femoropopliteal disease reduced restenosis
nd TLR. The TLR 2 years after EVT was 82% in the
ilostazol group in this report, which is similar to the rate of
7% in the cilostazol group in our study. We note that the
atients in the cilostazol group in the study by Iida et al. (8)
ad a longer lesion (mean lesion length, 141 mm) and more
cclusive disease compared with our patients, and 29% had
ritical limb ischemia, which suggests that their lesion
ackground was more severe.
The use and type of stent were determined by the
perator, The nitinol stent is known to improve the long-
erm patency rate compared with conventional stents (2).
owever, stent fracture is an important factor in restenosis
fter stent implantation (9–11). Stent implantation was
erformed in 36 (46.2%) patients and a fracture was found
n 3 (8.3%); however, these were only minor fractures and
o restenosis occurred at the fracture site. A drug-eluting
tent was implanted in native coronary artery in 14 (18%)
atients who continued to receive ticlopidine at the discre-
ion of the operator. Six of these patients also received
ilostazol; therefore, they underwent triple antiplatelet ther-
py with aspirin, ticlopidine, and cilostazol. However, no
ajor bleeding complications developed during the obser-
ation period. We note that cilostazol alone or in combi-
ation with other antiplatelet agents has previously been
eported not to increase bleeding (12). In coronary artery
isease, cilostazol reduces restenosis and repeat revascular-
zation and appears to be safe, with no significant increase in
he risk of bleeding, in a meta-analysis of randomized
linical trials comparing cilostazol with control therapy after
oronary intervention (5). Our study gave a similar result for
ilostazol administration in patients with femoropopliteal
isease after EVT.
There are several possible reasons why oral administration
f cilostazol reduced TVR. First, cilostazol is a stronger
ntiplatelet agent than aspirin, dipyridamole, and ticlopi-
ine (13,14), and consequently, it has a more rapid effect
15). The TASC II guidelines (3) also recommend oral
dministration of antiplatelet agents to prevent early occlu-
ion by thrombus at the treated site. A second reason is the
eduction of restenosis caused by proliferation of neointima.
linical study has shown cilostazol-associated suppression
f neointimal hyperplasia (16). A third reason for the effect
f cilostazol may be reduction in symptoms due to vasodi-
ation induced by continuous relaxation of vascular smooth
uscle. Several studies have reported that oral administra-
ion of cilostazol improves the walking distance and symp-
oms of PAD patients (17–20), and vasodilation may
ontribute to reduction of repeat revascularization.
A subgroup analysis was performed on patients with
cclusive (n  24) and nonocclusive (n  52) diseases.
ilostazol administration reduced the rate of TVR in
atients with nonocclusive disease (3.4% vs. 39%, p 
.001), but not in patients with occlusive disease (50% vs.6%, p  0.48). The lesion length was longer (187  73
m vs. 98  58 mm, p  0.0001) and stent placement was
ore frequent (66.7% vs. 38.5%, p  0.02) in patients with
cclusive disease than it was in patients with nonocclusive
isease. The higher rate of stenting in patients with occlu-
ive disease was due to suboptimal results after balloon
ngioplasty; therefore, these patients are likely to have
oorer characteristics. These subgroups were not established
efore the study, and the sample size was too small to
valuate whether the findings are due to a lack of treatment
fficacy. The 24 patients with total occlusion were also
lassified into stent (n  16; mean stent length, 165  74
m) and nonstent (n  8) groups. The lesion length was
onger in the stent group than in the nonstent group (207
5 mm vs. 147  80 mm, p  0.05), but the rates of TLR
18.8% vs. 62.5%, p  0.03) and TVR (25% vs. 75%, p 
.02) and the reocclusion rate (12.5% vs. 50%, p  0.05)
ere significantly lower in the stent group.
tudy limitations. In interpreting our results, we note that
he study has several limitations. First, it was designed to be
prospective randomized study, but was not double-blinded
nd only had a small sample size. Second, the clinical
ecision to perform TVR may have been biased, but to
ompensate for this limitation, TVR was performed after
onfirmation of ischemia-driven symptoms.
onclusions
ong-term administration of antiplatelet agents is recom-
ended for symptomatic PAD patients, but indications and
ppropriate agents have not been established. Therefore, the
esults of the current study are significant, because they show
hat a combination of cilostazol and aspirin reduces revascu-
arization. Further studies involving PAD patients after EVT
re required to establish the effect of treatment with cilostazol.
owever, the current results allow the conclusion that cilosta-
ol reduces restenosis and repeat revascularization after EVT
or femoropopliteal disease in claudicant patients.
eprint requests and correspondence: Dr. Hiroyoshi Yokoi,
epartment of Cardiology, Kokura Memorial Hospital, 1-1
ifune-machi, Kokurakita-ku, Kitakyushu 802-8555, Japan.
-mail: hyokoi@bu.iij4u.or.jp.
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